Specialty pharmaceuticals are expected to eventually replace non-specialty agents for the management of various conditions, including gout, lupus, diabetes, and hypercholesterolemia.
Specialty pharmaceuticals are expected to eventually replace non-specialty agents for the management of various conditions, including gout, lupus, diabetes, and hypercholesterolemia. This is according to research presented during the Academy of Managed Care Pharmacy's 2010 Educational Conference in St. Louis.
Pharmaceutical manufacturers are focusing research efforts on biosimilars or bio-betters. Bio-betters are new dosage forms or more targeted approaches for biologics, like "product-line extensions" for these agents. It is anticipated that in 10 years, 25% of specialty products will be biogenerics-a significant change.
Additionally, there will be more orphan drugs and oncology agents that garner FDA approval. Most recently two-thirds of approvals for specialty pharmaceuticals were for orphan drugs to treat rare cancer types. In the future, biogenetic testing may be combined with these approvals to greater enhance efficacy and safety.
Current leading specialty categories include inflammatory conditions, MS, cancer, HCV, lysosomal storage disorders, cystic fibrosis, and HIV-related lipodystrophy. There likely will be new biologics with novel mechanisms of action to treat lupus, gout, cystic fibrosis, rheumatoid arthritis (RA), psoriasis, and psoriatic arthritis (PsA). Some of these potential new agents will be oral, such as tasocitinib (RA, psoriasis) and apremilast (psoriasis, PsA). The MS pipeline is robust with laquinimod, Tovaxin, dimethyl fumarate, and teriflunomide. Dimethyl fumarate and teriflunomide are oral.
The more than 4 million patients with HCV are soon to get some good news-a pipeline rich with novel agents, including 2 oral protease inhibitors, telaprevir and boceprevir, which provide a greater sustained virological response than currently available agents.
According to Aimee Tharaldson, PharmD, senior clinical consultant of emerging therapeutics at Express Scripts, "These new oral agents fill a significant unmet need for HCV patients since they dramatically improve viral 'cure' rates. Several years from now, it is possible that there will be an all 'oral drug' cocktail to treat HCV, similar to how HIV is now treated."
For treating HIV-associated lipodystrophy, tesamorelin was approved on November 10, 2010, and is the first drug approved for this condition.
Coalition promotes important acetaminophen dosing reminders
November 18th 2014It may come as a surprise that each year Americans catch approximately 1 billion colds, and the Centers for Disease Control and Prevention estimates that as many as 20% get the flu. This cold and flu season, 7 in 10 patients will reach for an over-the-counter (OTC) medicine to treat their coughs, stuffy noses, and sniffles. It’s an important time of the year to remind patients to double check their medicine labels so they don’t double up on medicines containing acetaminophen.
Support consumer access to specialty medications through value-based insurance design
June 30th 2014The driving force behind consumer cost-sharing provisions for specialty medications is the acquisition cost and not clinical value. This appears to be true for almost all public and private health plans, says a new report from researchers at the University of Michigan Center for Value-Based Insurance Design (V-BID Center) and the National Pharmaceutical Council (NPC).
Management of antipsychotic medication polypharmacy
June 13th 2013Within our healthcare-driven society, the increase in the identification and diagnosis of mental illnesses has led to a proportional increase in the prescribing of psychotropic medications. The prevalence of mental illnesses and subsequent treatment approaches may employ monotherapy as first-line treatment, but in many cases the use of combination of therapy can occur, leading to polypharmacy.1 Polypharmacy can be defined in several ways but it generally recognized as the use of multiple medications by one patient and the most common definition is the concurrent use of five more medications. The presence of polyharmacy has the potential to contribute to non-compliance, drug-drug interactions, medication errors, adverse events, or poor quality of life.
Medical innovation improves outcomes
June 12th 2013I have been diagnosed with stage 4 cancer of the pancreas, a disease that’s long been considered not just incurable, but almost impossible to treat-a recalcitrant disease that some practitioners feel has given oncology a bad name. I was told my life would be measured in weeks.